{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:50:34Z","timestamp":1789026634336,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10915-5","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T13:42:04Z","timestamp":1744292524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical utility of oral Nemonoxacin 500\u00a0mg once daily for the treatment of acute lower urinary tract infections: a prospective open-label, multicenter study"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhen","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiehuan","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludong","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"12","key":"10915_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrurol.2010.190","volume":"7","author":"B Foxman","year":"2010","unstructured":"Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653\u201360. https:\/\/doi.org\/10.1038\/nrurol.2010.190.","journal-title":"Nat Rev Urol"},{"key":"10915_CR2","unstructured":"CHINET. China antimicrobial surveillance network (CHINET). http:\/\/www.chinets.com\/Data\/AntibioticDrugFast. Date Accessed: April 24, 2023."},{"issue":"suppl2","key":"10915_CR3","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1093\/cid\/ciy657","volume":"67","author":"F Hu","year":"2018","unstructured":"Hu F, Zhu D, Wang F, Wang M. Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018;67(suppl2):S128\u201334. https:\/\/doi.org\/10.1093\/cid\/ciy657.","journal-title":"Clin Infect Dis"},{"key":"10915_CR4","doi-asserted-by":"crossref","unstructured":"Kline KA, Lewis AL, Gram-Positive, Uropathogens. Polymicrobial urinary tract infection, and the emerging microbiota of the urinary tract. Microbiol Spectr. 2016;4(2). 10.1128. \/microbiolspec.UTI-0012-2012.","DOI":"10.1128\/microbiolspec.UTI-0012-2012"},{"issue":"1","key":"10915_CR5","doi-asserted-by":"publisher","first-page":"17658","DOI":"10.1038\/s41598-020-74834-y","volume":"10","author":"M Gajd\u00e1cs","year":"2020","unstructured":"Gajd\u00e1cs M, \u00c1br\u00f3k M, L\u00e1z\u00e1r A, Buri\u00e1n K. Increasing relevance of Gram-positive Cocci in urinary tract infections: a 10-year analysis of their prevalence and resistance trends. Sci Rep. 2020;10(1):17658. https:\/\/doi.org\/10.1038\/s41598-020-74834-y.","journal-title":"Sci Rep"},{"issue":"1","key":"10915_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1128\/AAC.00683-09","volume":"54","author":"DT Chung","year":"2010","unstructured":"Chung DT, Tsai CY, Chen SJ, et al. Multiple-dose safety, tolerability, and pharmacokinetics of oral Nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):411\u20137. https:\/\/doi.org\/10.1128\/AAC.00683-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10915_CR7","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40265-014-0270-0","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM. Nemonoxacin: first global approval. Drugs. 2014;74(12):1445\u201353. https:\/\/doi.org\/10.1007\/s40265-014-0270-0.","journal-title":"Drugs"},{"key":"10915_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/DDDT.S63581","volume":"8","author":"X Qin","year":"2014","unstructured":"Qin X, Huang H. Review of Nemonoxacin with special focus on clinical development. Drug Des Devel Ther. 2014;8:765\u201374. https:\/\/doi.org\/10.2147\/DDDT.S63581.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10915_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jmii.2017.07.011","volume":"52","author":"J Yuan","year":"2019","unstructured":"Yuan J, Mo B, Ma Z, Investigator Group of the Phase 3 Study on Oral Nemonoxacin, et al. Safety and efficacy of oral Nemonoxacin versus Levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. J Microbiol Immunol Infect. 2019;52(1):35\u201344. https:\/\/doi.org\/10.1016\/j.jmii.2017.07.011.","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"10915_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jmii.2018.11.006","volume":"52","author":"SL Cheng","year":"2019","unstructured":"Cheng SL, Wu RG, Chuang YC, et al. Integrated safety summary of phase II and III studies comparing oral Nemonoxacin and Levofloxacin in community-acquired pneumonia. J Microbiol Immunol Infect. 2019;52(5):743\u201351. https:\/\/doi.org\/10.1016\/j.jmii.2018.11.006.","journal-title":"J Microbiol Immunol Infect"},{"key":"10915_CR11","doi-asserted-by":"publisher","first-page":"1067686","DOI":"10.3389\/fphar.2022.1067686","volume":"13","author":"J Yuan","year":"2022","unstructured":"Yuan J, Zhang X, Chen J, Zhang Y, Zhu F, Huang H. Safety of oral Nemonoxacin: A systematic review of clinical trials and postmarketing surveillance. Front Pharmacol. 2022;13:1067686. https:\/\/doi.org\/10.3389\/fphar.2022.1067686.","journal-title":"Front Pharmacol"},{"issue":"7","key":"10915_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/11632780-000000000-00000","volume":"32","author":"B Guo","year":"2012","unstructured":"Guo B, Wu X, Zhang Y, et al. Safety and clinical pharmacokinetics of Nemonoxacin, a novel non-fluorinated Quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig. 2012;32(7):475\u201386. https:\/\/doi.org\/10.2165\/11632780-000000000-00000.","journal-title":"Clin Drug Investig"},{"key":"10915_CR13","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.2147\/IDR.S248092","volume":"13","author":"B Zhao","year":"2020","unstructured":"Zhao B, Yu X, Chen R, Zheng R. Efficacy and safety of Nemonoxacin in outpatients with Community-Acquired pneumonia. Infect Drug Resist. 2020;13:2099\u2013104. https:\/\/doi.org\/10.2147\/IDR.S248092.","journal-title":"Infect Drug Resist"},{"issue":"7","key":"10915_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1089\/mdr.2016.0021","volume":"22","author":"S Roychoudhury","year":"2016","unstructured":"Roychoudhury S, Makin K, Twinem T, Leunk R, Hsu MC. In vitro resistance development to Nemonoxacin in Streptococcus pneumoniae: A unique profile for a novel nonfluorinated quinolone. Microb Drug Resist. 2016;22(7):578\u201384. https:\/\/doi.org\/10.1089\/mdr.2016.0021.","journal-title":"Microb Drug Resist"},{"issue":"12","key":"10915_CR15","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s10096-019-03673-1","volume":"38","author":"F Hu","year":"2019","unstructured":"Hu F, Guo Y, Yang Y, China Antimicrobial Surveillance Network (CHINET) Study Group, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275\u201381. https:\/\/doi.org\/10.1007\/s10096-019-03673-1.","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10915-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T13:42:07Z","timestamp":1744292527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10915-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10915"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10915-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was approved by the ethics committee of Beijing Tongren Hospital, Capital Medical University (approval number: TREC2021-57). This study is conducted in compliance with the principles of the Declaration of Helsinki. This study was registered in Chinese Clinical Trial Registry (identifier: ChiCTR2100046585) on May 22, 2021. Each participant signed an informed consent before the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Chinese Clinical Trial Registry (ChiCTR2100046585). Registered on May 22, 2021.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}],"article-number":"501"}}